Genetic Determinants and Epidemiology of Cystic Fibrosis–Related Diabetes

OBJECTIVE—Longer survival of patients with cystic fibrosis has increased the occurrence of cystic fibrosis–related diabetes (CFRD). In this study we documented the incidence of CFRD and evaluated the association between mutations responsible for cystic fibrosis and incident CFRD, while identifying potential risk factors. RESEARCH DESIGN AND METHODS—This was a population-based longitudinal study of 50 cystic fibrosis speciality clinics in the U.K. Subjects included 8,029 individuals aged 0–64 years enrolled in the U.K. Cystic Fibrosis Registry during 1996–2005. Of these, 5,196 with data and without diabetes were included in analyses of incidence, and 3,275 with complete data were included in analyses of risk factors. Diabetes was defined by physician diagnosis, oral glucose tolerance testing, or treatment with hypoglycemic drugs. RESULTS—A total of 526 individuals developed CFRD over 15,010 person-years. The annual incidence was 3.5%. The incidence was higher in female patients and in patients with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in classes I and II. In a multivariate model of 377 cases of 3,275 patients, CFTR class (relative risk 1.70 [95% CI 1.16–2.49], class I or II versus others), increasing age, female sex, worse pulmonary function, liver dysfunction, pancreatic insufficiency, and corticosteroid use were independently associated with incident diabetes. CONCLUSIONS—The incidence of CFRD is high in Britain. CFTR class I and II mutations increase the risk of diabetes independent of other risk factors including pancreatic exocrine dysfunction.

[1]  P. Raskin,et al.  The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. , 2005, The American journal of medicine.

[2]  B. Strandvik,et al.  Presence of cystic fibrosis‐related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: Data from the European Epidemiologic Registry of Cystic Fibrosis , 2001, Pediatric pulmonology.

[3]  D. Barton,et al.  Genotype analysis in cystic fibrosis in relation to the occurrence of diabetes mellitus , 1993, Clinical genetics.

[4]  P. Lebecque,et al.  Glucose homeostasis and genotype-phenotype interplay in cystic fibrosis patients with CFTR gene deltaF508 mutation. , 2007, Diabetes care.

[5]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[6]  T. Flotte,et al.  Cystic Fibrosis Transmembrane Conductance Regulator Deficiency Exacerbates Islet Cell Dysfunction After β-Cell Injury , 2006, Diabetes.

[7]  M. Rosenfeld,et al.  Gender gap in cystic fibrosis mortality. , 1997, American journal of epidemiology.

[8]  S. Butler,et al.  Epidemiology of cystic fibrosis-related diabetes. , 2005, The Journal of pediatrics.

[9]  J. Rosenecker,et al.  Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. , 2001, European journal of medical research.

[10]  A. Moran,et al.  Abnormal glucose metabolism in cystic fibrosis. , 1998, The Journal of pediatrics.

[11]  E. Sims,et al.  Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. , 2005, Diabetes care.

[12]  J. Rosenecker,et al.  Genetic determination of diabetes mellitus in patients with cystic fibrosis. Multicenter Cystic Fibrosis Study Group. , 1995, The Journal of pediatrics.

[13]  D. Cucinotta,et al.  Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10‐year follow‐up study , 1999, Acta paediatrica.

[14]  B. Strandvik,et al.  European Epidemiologic Registry of Cystic Fibrosis (ERCF): Comparison of major disease manifestations between patients with different classes of mutations , 2001, Pediatric pulmonology.

[15]  M. Corey,et al.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas , 2003, Gut.

[16]  W. Malaisse,et al.  Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas , 2007, Endocrine.

[17]  B. Thorsteinsson,et al.  Glucose tolerance in patients with cystic fibrosis: five year prospective study , 1995, BMJ.

[18]  T. Hyde,et al.  Cystic fibrosis transmembrane conductance regulator expression in human hypothalamus , 1998, Neuroreport.

[19]  R. Rowntree,et al.  The Phenotypic Consequences of CFTR Mutations , 2003, Annals of human genetics.

[20]  S. Conway,et al.  Diagnosis and Treatment of Intestinal Malabsorption in Cystic Fibrosis , 2006, Pediatric pulmonology.

[21]  P. Saavedra-Santana,et al.  Carbohydrate Metabolism Changes in Cystic Fibrosis , 2007, Journal of pediatric endocrinology & metabolism : JPEM.

[22]  A. Adler,et al.  Characteristics of adults with and without cystic fibrosis‐related diabetes , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[23]  A. Galli-Tsinopoulou,et al.  Insulin improves clinical status of patients with cystic‐fibrosis‐related diabetes mellitus , 2001, Acta paediatrica.

[24]  A. Moran,et al.  Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. , 2005, Diabetes care.

[25]  S. Emerson,et al.  Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study , 2003, The Lancet.